Die endokrin-basierte Therapie des Mammakarzinoms

Prof. Dr. med. Peter A. Fasching

Honorar- und Beratertätigkeit: Novartis, Biontech, Pfizer, Daiichi-Sankyo, AstraZeneca, Eisai, Merck Sharp&Dohme, Cepheid, Lilly, Pierre Fabre, SeaGen, Roche, Agendia, Sanofi Aventin, Gilead, Mylan, Menarini, Medac

PD Dr. med. Mattea Reinisch

Honorar- und Beratertätigkeit: AstraZeneca, Daiichi Sankyo, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, Seagen and Somatex

Prof. Dr. med. Marc Thill

Advisory Board: Amgen, AstraZeneca, Biom‘Up, Canon, Clearcut, Clovis, Daiichi Sankyo, Eisai, Exact Sciences, Gilead Sciences, Grünenthal, GSK, Lilly, MSD, Norgine, Neodynamics, Novartis, Onkowissen, Organon, Pfizer, pfm medical, Pierre-Fabre, Roche, RTI Surgical, Seagen, Sirius Medical, Sysmex, Vortragshonorare: Amgen, art tempi, AstraZeneca, Canon, Clovis, Celgene, Connect Medica, Daiichi Sankyo, Eisai, Exact Sciences, Gedeon Richter, Gilead Sciences, GSK, Hexal, I-Med-Institute, Laborarztpraxis Walther, Lilly, MCI, Medscape, Medtronic, MSD, Novartis, Onkowissen, Organon, Pfizer, pfm medical, Roche, RTI Surgical, Seagen, Sirius Medical, StreamedUp!, Sysmex, Viatris, Vifor, Manuskriptunterstützung: Amgen, Clearcut, Clovis, pfm medical, Organon, Roche, Servier, Trial funding: Endomag, Exact Sciences, Industrie-Studienhonorare: AstraZeneca, Biom‘Up, Celgene, Clearcut, Neodynamics, Novartis, pfm medical, RTI Surgical